Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers
Open Access
- 28 November 2006
- journal article
- research article
- Published by Wiley in Proteomics
- Vol. 6 (23), 6277-6287
- https://doi.org/10.1002/pmic.200600135
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Proteomics in pathology researchLaboratory Investigation, 2004
- Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy personsProteomics, 2003
- A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's diseaseProteomics, 2003
- Proteomic Approaches to the Diagnosis, Treatment, and Monitoring of CancerPublished by Springer Nature ,2003
- Tissue Polypeptide-Specific Antigen (TPS) Concentrations in Cerebrospinal Fluid in Patients with Breast Cancer Metastases in the Central Nervous Systemcclm, 2001
- Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasisAnnals of Neurology, 1995
- Cerebrospinal fluid tumour markers in patients treated for meningeal malignancy.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- Creatine kinase-BB in the cerebrospinal fluid as a marker of CNS metastases and leptomeningeal carcinomatosis in patients with breast cancerEuropean Journal of Cancer and Clinical Oncology, 1989
- Cerebrospinal fluid tumor markers for the diagnosis and management of leptomeningeal metastasesEuropean Journal of Cancer and Clinical Oncology, 1987
- Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patientsCancer, 1982